These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 26023178)

  • 21. Use of the wearable cardioverter defibrillator in high-risk cardiac patients: data from the Prospective Registry of Patients Using the Wearable Cardioverter Defibrillator (WEARIT-II Registry).
    Kutyifa V; Moss AJ; Klein H; Biton Y; McNitt S; MacKecknie B; Zareba W; Goldenberg I
    Circulation; 2015 Oct; 132(17):1613-9. PubMed ID: 26316618
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy.
    Maron BJ; Shen WK; Link MS; Epstein AE; Almquist AK; Daubert JP; Bardy GH; Favale S; Rea RF; Boriani G; Estes NA; Spirito P
    N Engl J Med; 2000 Feb; 342(6):365-73. PubMed ID: 10666426
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Arrhythmias in cardiomyopathies].
    Kaneko Y; Kurabayashi M
    Nihon Rinsho; 2002 Jul; 60(7):1434-9. PubMed ID: 12136626
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Factors predisposing to ventricular tachyarrhythmia leading to appropriate ICD intervention in patients with coronary artery disease or non-ischaemic dilated cardiomyopathy.
    Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
    Kardiol Pol; 2012; 70(12):1264-75. PubMed ID: 23264245
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Myocardial fibrosis predicts appropriate device therapy in patients with implantable cardioverter-defibrillators for primary prevention of sudden cardiac death.
    Iles L; Pfluger H; Lefkovits L; Butler MJ; Kistler PM; Kaye DM; Taylor AJ
    J Am Coll Cardiol; 2011 Feb; 57(7):821-8. PubMed ID: 21310318
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sudden death related cardiomyopathies - Arrhythmogenic right ventricular cardiomyopathy, arrhythmogenic cardiomyopathy, and exercise-induced cardiomyopathy.
    Goff ZD; Calkins H
    Prog Cardiovasc Dis; 2019; 62(3):217-226. PubMed ID: 31004608
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HRS/ACC/AHA expert consensus statement on the use of implantable cardioverter-defibrillator therapy in patients who are not included or not well represented in clinical trials.
    Kusumoto FM; Calkins H; Boehmer J; Buxton AE; Chung MK; Gold MR; Hohnloser SH; Indik J; Lee R; Mehra MR; Menon V; Page RL; Shen WK; Slotwiner DJ; Stevenson LW; Varosy PD; Welikovitch L
    Circulation; 2014 Jul; 130(1):94-125. PubMed ID: 24815500
    [No Abstract]   [Full Text] [Related]  

  • 28. Late gadolinium enhancement cardiac magnetic resonance imaging for the prediction of ventricular tachyarrhythmic events: a meta-analysis.
    Scott PA; Rosengarten JA; Curzen NP; Morgan JM
    Eur J Heart Fail; 2013 Sep; 15(9):1019-27. PubMed ID: 23558217
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sudden cardiac death in nonischemic cardiomyopathy.
    Kadakia RS; Link MS; Dominic P; Morin DP
    Prog Cardiovasc Dis; 2019; 62(3):235-241. PubMed ID: 31075279
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of CMR imaging in risk stratification for sudden cardiac death.
    Aljaroudi WA; Flamm SD; Saliba W; Wilkoff BL; Kwon D
    JACC Cardiovasc Imaging; 2013 Mar; 6(3):392-406. PubMed ID: 23473115
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic role of post-infarction C-reactive protein in patients undergoing implantation of cardioverter-defibrillators: design of the C-reactive protein Assessment after Myocardial Infarction to GUide Implantation of DEfibrillator (CAMI GUIDE) study.
    Bellocci F; Biasucci LM; Gensini GF; Padeletti L; Raviele A; Santini M; Giubilato G; Landolina M; Biondi-Zoccai G; Raciti G; Sassara M; Castro A; Kheir A; Crea F
    J Cardiovasc Med (Hagerstown); 2007 Apr; 8(4):293-9. PubMed ID: 17413310
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Implantable defibrillators in ischaemic cardiomyopathy: should women be treated differently to men?
    Leung DY
    Heart; 2014 Feb; 100(3):190-1. PubMed ID: 24270745
    [No Abstract]   [Full Text] [Related]  

  • 33. Prediction of ventricular arrhythmia events in ischemic heart disease patients with implantable cardioverter-defibrillators.
    Feng T; Zhang S; Chen K; Hua W; Ren X
    J Mater Sci Mater Med; 2015 Oct; 26(10):240. PubMed ID: 26411436
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sudden death prevention with implantable devices.
    Passman R; Kadish A
    Circulation; 2007 Jul; 116(5):561-71. PubMed ID: 17664385
    [No Abstract]   [Full Text] [Related]  

  • 35. Current practice in Europe: how do we manage patients with ventricular tachycardia? European Heart Rhythm Association survey.
    Proclemer A; Dagres N; Marinskis G; Pison L; Lip GY; Blomstrom-Lundqvist C;
    Europace; 2013 Feb; 15(2):167-9. PubMed ID: 23334717
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The automated implantable cardiac defibrillator. Prophylaxis in cardiac sarcoidosis.
    Paz HL; McCormick DJ; Kutalek SP; Patchefsky A
    Chest; 1994 Nov; 106(5):1603-7. PubMed ID: 7956431
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Are implantable cardioverter defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic cardiomyopathy?
    Ellenbogen KA; Levine JH; Berger RD; Daubert JP; Winters SL; Greenstein E; Shalaby A; Schaechter A; Subacius H; Kadish A;
    Circulation; 2006 Feb; 113(6):776-82. PubMed ID: 16461817
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Determinants of patient survival rate after implantation of a cardioverter-defibrillator without resynchronisation capability.
    Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
    Kardiol Pol; 2012; 70(11):1099-110. PubMed ID: 23180517
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Updated ESC guideline: innovations for the treatment of ventricular arrhythmias and recommendations for prevention of sudden cardiac death].
    Eckardt L; Deneke T
    Herzschrittmacherther Elektrophysiol; 2016 Sep; 27(3):288-94. PubMed ID: 27581243
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical management and prevention of sudden cardiac death.
    Yousuf O; Chrispin J; Tomaselli GF; Berger RD
    Circ Res; 2015 Jun; 116(12):2020-40. PubMed ID: 26044254
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.